Erythropoietin Stimulates Tumor Growth via EphB4.

While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo's effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo-induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.

[1]  H. Arai,et al.  Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. , 2008, Neoplasia.

[2]  J. Glaspy.  Hematology: ESAs to treat anemia—balancing the risks and benefits , 2009, Nature Reviews Clinical Oncology.

[3]  Prahlad T. Ram,et al.  2′-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity , 2014, Nature Communications.

[4]  Michael A. Yamin,et al.  Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin , 2008, Proceedings of the National Academy of Sciences.

[5]  Peter J McCormick,et al.  EphB2 and EphB4 receptors forward signaling promotes SDF-1-induced endothelial cell chemotaxis and branching remodeling. , 2006, Blood.

[6]  Gao Zhang,et al.  Erythropoietin Receptor Contributes to Melanoma Cell Survival in vivo , 2011, Oncogene.

[7]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[8]  Andrew K. Sewell,et al.  The CD8 T Cell Coreceptor Exhibits Disproportionate Biological Activity at Extremely Low Binding Affinities* , 2003, Journal of Biological Chemistry.

[9]  M. Diederich,et al.  Erythropoietin, erythropoiesis and beyond. , 2011, Biochemical pharmacology.

[10]  A. Xenocostas,et al.  The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression , 2011, Clinical Cancer Research.

[11]  M. Wendland,et al.  Erythropoietin Improves Functional and Histological Outcome in Neonatal Stroke , 2005, Pediatric Research.

[12]  Liz Y. Han,et al.  Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma , 2006, Nature Medicine.

[13]  Dieter Braun,et al.  Molecular interaction studies using microscale thermophoresis. , 2011, Assay and drug development technologies.

[14]  Justine R. Smith,et al.  Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells. , 2009, Microvascular research.

[15]  B. Leyland-Jones,et al.  Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer , 2012, British Journal of Cancer.

[16]  J. Krosl,et al.  Interleukin-3 (IL-3) Inhibits Erythropoietin-induced Differentiation in Ba/F3 Cells via the IL-3 Receptor α Subunit* , 1996, The Journal of Biological Chemistry.

[17]  A. Sood,et al.  Focal Adhesion Kinase Silencing Augments Docetaxel-Mediated Apoptosis in Ovarian Cancer Cells , 2005, Clinical Cancer Research.

[18]  C. Noguchi,et al.  Role of erythropoietin in the brain. , 2007, Critical reviews in oncology/hematology.

[19]  R. Bast,et al.  SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. , 2010, Cancer cell.

[20]  E B Cox,et al.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. , 1985, Archives of pathology & laboratory medicine.

[21]  Robert M. Stroud,et al.  Efficiency of signalling through cytokine receptors depends critically on receptor orientation , 1998, Nature.

[22]  A. Sytkowski.  Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells , 2007, Science's STKE.

[23]  R. Perona,et al.  Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells , 2007, Cancer biology & therapy.

[24]  E. Desantis,et al.  Use of erythropoietin-stimulating agents in breast cancer patients: a risk review. , 2009, American Journal of Health-System Pharmacy.

[25]  Manfred Auer,et al.  Structural and Biophysical Characterization of the EphB4·EphrinB2 Protein-Protein Interaction and Receptor Specificity* , 2006, Journal of Biological Chemistry.

[26]  B. Desbuquois,et al.  Glucagon receptors , 2008, Cellular and Molecular Life Sciences.

[27]  G. Calin,et al.  Hypoxia Mediated Downregulation of miRNA Biogenesis Promotes Tumor Progression , 2014, Nature Communications.

[28]  Prahlad T. Ram,et al.  Hematogenous metastasis of ovarian cancer: rethinking mode of spread. , 2014, Cancer cell.

[29]  Lois E. H. Smith,et al.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. , 2009, Investigative ophthalmology & visual science.

[30]  Hai-gang Li,et al.  Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma. , 2011, World journal of gastroenterology.

[31]  A. Cerami,et al.  The Receptor That Tames the Innate Immune Response , 2012, Molecular medicine.

[32]  L. Kassem,et al.  Role of erythropoeitin in prevention of chemotherapy-induced peripheral neuropathy. , 2010, Pakistan journal of biological sciences : PJBS.

[33]  J. Glaspy.  Erythropoietin in cancer patients. , 2009, Annual review of medicine.

[34]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[35]  M. Arcasoy,et al.  Erythropoietin for oncology supportive care. , 2011, Experimental cell research.

[36]  R. Foley,et al.  Erythropoietin: physiology and molecular mechanisms , 2008, Heart Failure Reviews.

[37]  J. Pérez-Ruixo,et al.  Population Pharmacokinetics Meta-Analysis of Recombinant Human Erythropoietin in Healthy Subjects , 2007, Clinical pharmacokinetics.

[38]  A. Salahudeen,et al.  Nonerythropoietic Properties of Erythropoietin , 2011, Journal of Investigative Medicine.

[39]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[40]  P. Kuhn,et al.  Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. , 2006, Structure.

[41]  H. Steinkellner,et al.  Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor , 2010, European journal of clinical investigation.

[42]  Soldano Ferrone,et al.  HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma , 2008, Clinical Cancer Research.

[43]  J. Rosenbaum,et al.  Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. , 2005, Investigative ophthalmology & visual science.

[44]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[45]  Jan-Fang Cheng,et al.  Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.

[46]  Adesh K. Jain,et al.  Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. , 1990, Blood.

[47]  B. Döme,et al.  Erythropoietin in cancer: an update. , 2008, Current molecular medicine.